Goldman Sachs
IMNM icon

Goldman Sachs’s Immunome IMNM Stock Holding History

Goldman Sachs’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-53,700
Closed -$1.15M – 6730
2025
Q4 		$1.15M Buy
+53,700
New +$942K ﹤0.01% 5039

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Goldman Sachs's IMNM Position: Q1 2026 in Review

Goldman Sachs increased its Immunome (IMNM) stake by 46% in Q1 2026, buying an estimated $7.76M and bringing the position to 1,101,476 shares worth $24.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2262.

Goldman Sachs first reported a position in IMNM in Q1 2024 and has held it in 9 quarters since. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Goldman Sachs held 1,101,476 shares of Immunome worth $24.1M as of Q1 2026.
  • Goldman Sachs bought 348,751 Immunome shares in Q1 2026, an estimated $7.76M.
  • Immunome made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2262 holding.
  • Goldman Sachs first reported a position in Immunome in Q1 2024 and has held it in 9 quarters since.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.